All In Biotech

Drug Trial Radar · NCT05109663

A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects

A Single-Centre, Single-Administration, Dose-Escalation Study and A Single-Centre, Randomized, Open-Label, Two-cycle Crossover Food Effect Study of SKLB1028 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Apr 14, 2021

Primary completion

Jun 30, 2021

Study completion Jun 30, 2021

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.

Conditions

  • Healthy Subjects

Interventions

  • SKLB1028Drug

    SKLB1028, capsule, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events (TEAEs)Time frame: Throughout the study period, with an average of 10 days.
  2. Maximum plasma concentration (Cmax) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  3. Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  4. Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  5. Time to Cmax (Tmax) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  6. Terminal-elimination half-life (T1/2) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  7. Apparent volume of distribution (Vz/F) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose
  8. Apparent clearance (CLz/F) of SKLB1028 in Part 2Time frame: Pre-dose and multiple timepoints up to 144 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.